FBRX common stock will be immediately removed from Nasdaq and deregistered. Holders should expect zero trading liquidity on the exchange and likely a move to OTC markets or complete extinguishment of equity value. The 'matured, redeemed, or retired' designation suggests the securities may have been called or cancelled, any remaining equity value is likely zero. Do not hold through the delisting.
How the stock moved after the report
BEARISH VIEWSTOCK AT ENTRY AT T+1- T+0 · Aug 27 $76.99entry
- T+1 · 3mo ago 0.00%α +0.23% · $76.99
- T+5 · due 3mo ago Pending
- T+20 · due 8w ago Pending
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Nasdaq filed a Form 25-NSE with the SEC on August 27, 2026, to remove Forte Biosciences (FBRX) common stock from listing and deregister the security under Section 12(b) of the Exchange Act. The delisting is effective immediately, citing Rule 17 CFR 240.12d2-2(a)(3), which covers matured, redeemed, or retired securities. This is a terminal event for the publicly traded equity, the stock will cease trading on Nasdaq and the company's SEC reporting obligations under Section 12(b) will terminate.
Key Facts
- Nasdaq filed Form 25-NSE to delist Forte Biosciences common stock effective August 27, 2026.
- The delisting is under Rule 17 CFR 240.12d2-2(a)(3) for matured, redeemed, or retired securities.
- The filing was made by Nasdaq Stock Market LLC (filer) with Forte Biosciences as the subject company.
- The company's SEC file number is 001-38052 and the security is Common Stock.
- The delisting terminates the company's Section 12(b) registration and associated reporting obligations.
Financial Impact
Complete loss of public listing and trading liquidity for FBRX common stock. No financial figures available in the filing.
Risk Factors
- Complete loss of trading liquidity on Nasdaq
- Potential total loss of equity value if securities were redeemed or retired
- No further SEC reporting obligations, reduced transparency for any remaining over-the-counter trading
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (FBRX), Batch item 1 | 0001354457-26-000824 |
| Document: 0001354457-26-000824-index-headers.html | 0001354457-26-000824 |
| Document: 0001354457-26-000824-index.html | 0001354457-26-000824 |
| Document: 0001354457-26-000824.txt | 0001354457-26-000824 |
| 25-NSE Filing (FBRX), Batch item 5 | 0001354457-26-000824 |
| Document: 0001354457-26-000824-index-headers.html | 0001354457-26-000824 |
| Document: 0001354457-26-000824-index.html | 0001354457-26-000824 |
| Document: 0001354457-26-000824.txt | 0001354457-26-000824 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Viewing Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers